TENAYA THERAPEUTICS INC (TNYA)

Company Profile

Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. The company is headquartered in South San Francisco, California and currently employs 140 full-time employees. The company went IPO on 2021-07-30. The firm is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The firm is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Company’s adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.

Company Info

TENAYA THERAPEUTICS INC

171 Oyster Point Blvd., Suite 500

South San Francisco CALIFORNIA

P: 14158652066

CEO: Faraz Ali

Employees: 140

Website: https://www.tenayatherapeutics.com/